S&P 500   4,270.10 (-0.42%)
DOW   33,323.92 (-0.55%)
QQQ   358.84 (+0.16%)
AAPL   172.97 (+1.03%)
MSFT   317.98 (+0.71%)
META   303.31 (+1.03%)
GOOGL   132.78 (+1.47%)
AMZN   128.63 (+1.19%)
TSLA   249.48 (-0.30%)
NVDA   445.77 (+2.48%)
NIO   8.77 (-2.99%)
BABA   86.15 (-0.68%)
AMD   102.57 (-0.24%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.59 (-0.65%)
CGC   0.75 (-4.18%)
GE   108.53 (-1.83%)
DIS   80.99 (-0.07%)
AMC   7.96 (-0.38%)
PFE   33.47 (+0.90%)
PYPL   58.14 (-0.55%)
NFLX   378.73 (+0.30%)
S&P 500   4,270.10 (-0.42%)
DOW   33,323.92 (-0.55%)
QQQ   358.84 (+0.16%)
AAPL   172.97 (+1.03%)
MSFT   317.98 (+0.71%)
META   303.31 (+1.03%)
GOOGL   132.78 (+1.47%)
AMZN   128.63 (+1.19%)
TSLA   249.48 (-0.30%)
NVDA   445.77 (+2.48%)
NIO   8.77 (-2.99%)
BABA   86.15 (-0.68%)
AMD   102.57 (-0.24%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.59 (-0.65%)
CGC   0.75 (-4.18%)
GE   108.53 (-1.83%)
DIS   80.99 (-0.07%)
AMC   7.96 (-0.38%)
PFE   33.47 (+0.90%)
PYPL   58.14 (-0.55%)
NFLX   378.73 (+0.30%)
S&P 500   4,270.10 (-0.42%)
DOW   33,323.92 (-0.55%)
QQQ   358.84 (+0.16%)
AAPL   172.97 (+1.03%)
MSFT   317.98 (+0.71%)
META   303.31 (+1.03%)
GOOGL   132.78 (+1.47%)
AMZN   128.63 (+1.19%)
TSLA   249.48 (-0.30%)
NVDA   445.77 (+2.48%)
NIO   8.77 (-2.99%)
BABA   86.15 (-0.68%)
AMD   102.57 (-0.24%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.59 (-0.65%)
CGC   0.75 (-4.18%)
GE   108.53 (-1.83%)
DIS   80.99 (-0.07%)
AMC   7.96 (-0.38%)
PFE   33.47 (+0.90%)
PYPL   58.14 (-0.55%)
NFLX   378.73 (+0.30%)
S&P 500   4,270.10 (-0.42%)
DOW   33,323.92 (-0.55%)
QQQ   358.84 (+0.16%)
AAPL   172.97 (+1.03%)
MSFT   317.98 (+0.71%)
META   303.31 (+1.03%)
GOOGL   132.78 (+1.47%)
AMZN   128.63 (+1.19%)
TSLA   249.48 (-0.30%)
NVDA   445.77 (+2.48%)
NIO   8.77 (-2.99%)
BABA   86.15 (-0.68%)
AMD   102.57 (-0.24%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.59 (-0.65%)
CGC   0.75 (-4.18%)
GE   108.53 (-1.83%)
DIS   80.99 (-0.07%)
AMC   7.96 (-0.38%)
PFE   33.47 (+0.90%)
PYPL   58.14 (-0.55%)
NFLX   378.73 (+0.30%)
NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

$9.27
-0.29 (-3.03%)
(As of 12:55 PM ET)
Compare
Today's Range
$9.13
$9.40
50-Day Range
$8.95
$12.54
52-Week Range
$8.06
$25.47
Volume
2,067 shs
Average Volume
39,506 shs
Market Capitalization
$204.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.86

Acrivon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.4% Upside
$22.86 Price Target
Short Interest
Bearish
2.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Acrivon Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.64) to ($3.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

668th out of 969 stocks

Pharmaceutical Preparations Industry

319th out of 453 stocks


ACRV stock logo

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

ACRV Price History

ACRV Stock News Headlines

Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Q1 2023 Akoya Biosciences Inc Earnings Call
See More Headlines
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Company Calendar

Last Earnings
8/11/2023
Today
10/02/2023
Next Earnings (Estimated)
12/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.86
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+139.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-31,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.16 per share

Miscellaneous

Free Float
20,462,000
Market Cap
$211.02 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Peter Blume-Jensen M.D. (Age 60)
    Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer
    Comp: $1.01M
  • Ms. Kristina Masson M.B.A. (Age 42)
    Ph.D., Co-Founder, Exec. VP of Bus. Operations, Site Head, Treasurer, Sec. & Director
  • Mr. Rasmus Holm-Jorgensen (Age 52)
    Chief Financial Officer
    Comp: $1M
  • Dr. Eric J. Devroe Ph.D. (Age 45)
    Chief Operating Officer
    Comp: $614.78k
  • Ms. Katharine Peterson CPA
    VP of Fin. & Accounting
  • Dr. Adam D. Levy M.B.A.
    Ph.D., Sr. VP and Head of Investor Relations & Corp. Affairs
  • Mr. Bruce Close
    VP of Quality & Compliance
  • Ms. Mary-Alice Miller J.D. (Age 49)
    Gen. Counsel
  • Ms. Parvin Miah
    VP & Head of HR
  • Mr. Erick Gamelin M.D. (Age 66)
    Ph.D., Chief Medical Officer













ACRV Stock - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings
or view top-rated stocks.

What is Acrivon Therapeutics' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year target prices for Acrivon Therapeutics' stock. Their ACRV share price forecasts range from $17.00 to $26.00. On average, they anticipate the company's share price to reach $22.86 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price.
View analysts price targets for ACRV
or view top-rated stocks among Wall Street analysts.

How have ACRV shares performed in 2023?

Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV stock has decreased by 17.0% and is now trading at $9.56.
View the best growth stocks for 2023 here
.

When is Acrivon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023.
View our ACRV earnings forecast
.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its earnings results on Friday, August, 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.02.

What ETF holds Acrivon Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio.

When did Acrivon Therapeutics IPO?

(ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Acrivon Therapeutics' stock symbol?

Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV."

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acrivon Therapeutics' stock price today?

One share of ACRV stock can currently be purchased for approximately $9.56.

How much money does Acrivon Therapeutics make?

Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $211.02 million. The company earns $-31,170,000.00 in net income (profit) each year or ($7.18) on an earnings per share basis.

How can I contact Acrivon Therapeutics?

The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com.

This page (NASDAQ:ACRV) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -